Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy (PRRT)
Conditions
Keywords
Neuroendocrine Tumors, 90Y, 177Lu, PRRT
Brief summary
The rationale behind the purpose of this study lays on: * the evidence that PRRT could represent a valuable treatment for the majority of patients with neuroendocrine tumor (NET) in disease progression, operated or inoperable, presenting lesions expressing somatostatin receptors and for which standard treatments are not already available; * the current impossibility of acquiring on the market radiolabelled analogues of somatostatin used for PRRT with marketing authorisation; * the need to collect a larger case history than in previous studies; * the need to stratify the various histotypes based on the response obtained; * the need to define new treatment schemes that guarantee the maximum efficacy and the lowest possible toxicity - with low cumulative (and per cycle) activities radiopharmaceutical and according to the concept of dose hyperfractionation - with a view to an optimal balance between risk and benefit.
Interventions
RADIATIONLutetium-177 (177Lu)-DOTATOC
5 cycles of 3,7 e 5,55 gigabequerel (GBq) of 177Lu-DOTATOC every 8-10 weeks. Cumulative activity: 18,5 e 27,75 GBq
RADIATIONYttrium-90 (90Y)-DOTATOC
5 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks. Cumulative activity: 9,25 e 13,875 GBq
RADIATION177Lu-DOTATOC + 90Y-DOTATOC
3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC alternated with 2 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks. Cumulative activity: 18,5 e 27,75 GBq of 177Lu-DOTATOC and 9,25 e 13,875 GBq of 90Y-DOTATOC
RADIATIONRe-treatment 177Lu-DOTATOC
3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC every 8-10weeks. Cumulative activity: 11,1 e 16,65 GBq of 177Lu-DOTATOC
RADIATIONRe-treatment 90Y-DOTATOC
3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC
Sponsors
University Hospital of Ferrara
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Age ≥18 years, of both sexes, of any ethnicity; * 2\. Cyto-histological and immunohistochemical diagnosis of NET; * 3\. Evaluation of the cell proliferation index by studying Ki-67 and / or E3 ubiquitin-protein ligase (MIB-1). * 4\. Illness measurable according to RECIST 1.1 criteria by imaging conventional (CT with contrast medium or MRI with contrast medium) not earlier than two months with respect to enrollment; * 5\. Elevated expression of somatostatin receptors documented by PET-CT with 68Ga-DOTATOC in the target lesion (s). It is defined as high expression of somatostatin receptors a ratio of Maximum standardized uptake value (SUVmax) lesion / Mean standardized uptake value (SUVmean) muscle ≥ 4: 1 calculated with semi-quantitative analysis on examination PET-CT with 68Ga-DOTATOC; * 6\. Dosage of Chromogranin A (and any other specific markers) not prior to two months of enrollment; * 7\. Evaluation of glucose metabolism in the target lesion (s) by PET-CT with 18F-FDG; * 8\. Preserved haematological, hepatic and renal parameters, in particular: white blood cells ≥2500 / μL; platelets ≥ 90000 / μL; hemoglobin ≥ 9 gr / dL; creatinine ≤ 2 mg / dL; bilirubin ≤ 2.5 mg / dL * 9\. Eastern Cooperative Oncology Group (ECOG) performance status ≤2; * 10\. Life expectancy ≥ 6 months; * 11\. Stable or progressive disease, at any stage, both in operated patients that inoperable; * 12\. Absence of standard treatments already documented and of equal effectiveness; * 13\. Absence of surgical, chemotherapy and / or radiotherapy treatments for at least 30 days. On the other hand, patients in therapy with somatostatin analogues or biologics, such as mechanistic target of rapamycin (m-TOR) inhibitors; * 14\. Voluntary participation in the study by signing the consent form informed, after reading and complete understanding of the information notes.
Exclusion criteria
* 1\. Lack of the requirements listed above; * 2\. State of pregnancy; * 3\. Breastfeeding and relative refusal to suspend breastfeeding; * 4\. Participation in another therapeutic experimental clinical protocol in the four weeks prior to the PRRT; * 5\. Bone marrow invasion of disease\> 25% confirmed; * 6\. Previous extensive radiotherapy treatments.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease Control Rate | 12 months | Post-treatment evaluation will be performed with: * a clinical examination; * a comparative morphological re-evaluation, using version 1.1 of Response evaluation criteria in solid tumors (RECIST criteria) on Computed Tomography (CT); * a comparative functional re-evaluation, performed both on 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission computed tomography (PET/CT) and Gallium-68 (68Ga)-DOTATOC PET/CT using visual and semi-quantitative parameters (such as SUVmax). Based on all these parameters, Disease Control Rate will be labelled as: Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progression Disease (PD). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | 6 months | Progression free survival is defined as the time intercurrent from treatment start to the date of first observation of documented disease progression or death due to any cause. |
| Overall Survival | 6 months | Overall survival is defined as the time intercurrent from treatment start to the date of death due to any cause, or the date of last contact. |
| Evaluation of PRRT Safety | 6 months | The evaluation of Treatment-Emergent Adverse Events, defined as any G3/G4 toxicity. The evaluation will be performed during every treatment cycle and after 12, 18, 24, 30, 36 and 42 months after the last treatment cycle and will be based on version 4.0 of Common Terminology Criteria for Adverse Events (CTC-AE) toxicity criteria. |
| Evaluation of Quality of Life | 6 months | Quality of Life (QoL) will be evaluated with quality of life questionnaire, version 3 (QLQ-C30) by European Organisation for Research and Treatment of Cancer (EORTC). The questionnaire includes five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. |
Countries
Italy
Contacts
Primary ContactMirco Bartolomei, MD
Backup ContactLicia Uccelli, PhD
Outcome results
None listed